Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...